---
figid: PMC9459544__tau-11-08-1177-f4
pmcid: PMC9459544
image_filename: tau-11-08-1177-f4.jpg
figure_link: /pmc/articles/PMC9459544/figure/f4/
number: Figure 4
figure_title: ''
caption: 'AS-IV treatment protected renal function and pathological damage in the
  I/R-induced CDK model. (A) Determination of CRE levels in CKD model rats. (B) Determination
  of UREA levels in the CKD rat models. (C) H&E staining of kidney tissue from the
  CKD rat models. Magnification ×400. (D) PAS staining of kidney tissue from the CKD
  rat models. Magnification ×400. #P<0.05, ##P<0.01, compared to the sham operation
  group; **P<0.01, compared to the I/R group. CRE, creatinine; UREA, urea; AS-IV,
  Astragaloside IV; I/R, ischemia-reperfusion; CKD, chronic kidney disease.'
article_title: Astragaloside IV protects against ischemia/reperfusion (I/R)-induced
  kidney injury based on the Keap1-Nrf2/ARE signaling pathway.
citation: Yanyan Su, et al. Transl Androl Urol. 2022 Aug;11(8):1177-1188.
year: '2022'

doi: 10.21037/tau-22-505
journal_title: Translational Andrology and Urology
journal_nlm_ta: Transl Androl Urol
publisher_name: AME Publishing Company

keywords:
- Astragaloside IV
- acute kidney injury (AKI)
- chronic kidney injury
- keap1-Nrf2/ARE
- oxidative stress

---
